BMJ  2008;336:610-612 (15 March), doi:10.1136/bmj.39498.525706.AD

Practice

Guidelines

Diagnosis and treatment of prostate cancer: summary of NICE guidance

John Graham, lead consultant in clinical oncology1, Mark Baker, lead cancer clinician2, Fergus Macbeth, director3, Victoria Titshall, project manager3, on behalf of the Guideline Development Group

1 Taunton & Somerset NHS Foundation Trust, Musgrove Park Hospital, Taunton TA1 5DA, 2 Leeds Teaching Hospitals NHS Trust, St James’s University Hospital, Leeds LS9 7TF , 3 National Collaborating Centre for Cancer, Cardiff CF10 3AF

Correspondence to: J Graham john.graham@nhs.net

The first 150 words of the full text of this article appear below.

Prostate cancer is one of the commonest cancers in men. Each year there are about 35 000 new cases in England and Wales and over 9000 deaths. The clinical course can extend over many years and often involves many different healthcare professionals. Evidence exists of practice variation around the country and of patchy availability of certain treatments and procedures. This article highlights a selection of the most recent recommendations from the National Institute for Health and Clinical Excellence (NICE) on the diagnosis and treatment of prostate cancer.1

NICE recommendations are based on systematic reviews of the best available evidence. When minimal evidence is available, recommendations are based on the guideline development group’s opinion of what constitutes good practice. Evidence levels for the recommendations are given in italic in square brackets.

Men with prostate cancer can be faced with multiple treatment choices over many years. Healthcare professionals should:

Background
Methods
Future research

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Articles

Serum tumour markers: how to order and interpret them
C M Sturgeon, L C Lai, and M J Duffy
BMJ 2009 339: b3527. [Extract] [Full Text]

Commentary: controversies in NICE guidance on prostate cancer
Timothy J Wilt
BMJ 2008 336: 612-614. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

  • Sturgeon, C M, Lai, L C, Duffy, M J (2009). Serum tumour markers: how to order and interpret them. BMJ 339: b3527-b3527 [Full text]  
  • Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P. (2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem. 54: e11-e79 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

BAUS Comments on Diagnosis and treatment of prostate cancer: summary of NICE guidance
Anthony R Mundy, et al.
bmj.com, 19 Mar 2008 [Full text]
NICE guidance on prostate cancer and the role of active surveillance for low risk, localised disease
Howard P Marsh, et al.
bmj.com, 25 Mar 2008 [Full text]
Response to BAUS Comments
John Graham, et al.
bmj.com, 8 Apr 2008 [Full text]
Surveillance guideline goes too far
Laurence Klotz
bmj.com, 29 Apr 2008 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ